Perspective Therapeutics Inc’s filing revealed that its Director HENSON HEIDI acquired Company’s shares for reported $0.1 million on Dec 04 ’24. In the deal valued at $3.85 per share,25,975 shares were bought. As a result of this transaction, HENSON HEIDI now holds 25,975 shares worth roughly $64937.5.
Then, Spoor Johan M. bought 8,000 shares, generating $30,132 in total proceeds. Upon buying the shares at $3.77, the CEO now owns 36,257 shares.
Before that, Williamson Robert F III bought 6,266 shares. Perspective Therapeutics Inc shares valued at $22,814 were divested by the Director at a price of $3.64 per share. As a result of the transaction, Williamson Robert F III now holds 430,058 shares, worth roughly $1.08 million.
Scotiabank initiated its Perspective Therapeutics Inc [CATX] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $15. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in late November from “a Buy” to “a Neutral”. UBS began covering CATX with “Buy” recommendation on October 24, 2024. Wedbush started covering the stock on October 01, 2024. It rated CATX as “an Outperform”.
Price Performance Review of CATX
On Tuesday, Perspective Therapeutics Inc [AMEX:CATX] saw its stock fall -1.57% to $2.50. Over the last five days, the stock has gained 6.38%. Perspective Therapeutics Inc shares have fallen nearly -21.63% since the year began. Nevertheless, the stocks have fallen -76.42% over the past one year. While a 52-week high of $19.05 was reached on 01/24/25, a 52-week low of $2.32 was recorded on 03/04/25. SMA at 50 days reached $3.17, while 200 days put it at $9.20.
Levels Of Support And Resistance For CATX Stock
The 24-hour chart illustrates a support level at 2.42, which if violated will result in even more drops to 2.34. On the upside, there is a resistance level at 2.58. A further resistance level may holdings at 2.66. The Relative Strength Index (RSI) on the 14-day chart is 37.49, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.08, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.13%. Stochastics %K at 31.24% indicates the stock is a holding.
The most recent change occurred on September 25, 2024 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $21 price target.
